The cholesterol ester-transferase protein inhibitor anacetrapib reduced LDL-cholesterol levels in patients with heterozygous familial hypercholesterolaemia already receiving optimal lipid-lowering therapy. LDL-cholesterol levels were reduced in patients who received 100 mg oral anacetrapib for 52 weeks compared with those who were assigned placebo (placebo-adjusted percentage change −39.7%, 95% CI −45.7 to −33.7; P <0.001). This study shows that anacetrapib in addition to current lipid-lowering treatments can decrease atherogenic lipids in circulation, but whether anacetrapib can prevent cardiovascular events remains to be determined.
References
Kastelein, J. J. et al. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet 10.1016/S0140-6736(14)62115-2
Rights and permissions
About this article
Cite this article
Anacetrapib reduces LDL cholesterol in patients with heterozygous familial hypercholesterolaemia. Nat Rev Cardiol 12, 261 (2015). https://doi.org/10.1038/nrcardio.2015.52
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2015.52
